1. Home >
  2. M&A >
  3. Going Private >
  4. United States >
  5. California >
  6. Deerfield Management Acquires Singular Genomics

M&A Deal Summary

Deerfield Management Acquires Singular Genomics

On December 23, 2024, venture capital firm Deerfield Management acquired life science company Singular Genomics

Acquisition Highlights
  • This is Deerfield Management’s 3rd transaction in the Life Science sector.
  • This is Deerfield Management’s 6th transaction in the United States.
  • This is Deerfield Management’s 3rd transaction in California.

M&A Deal Summary
Date 2024-12-23
Target Singular Genomics
Sector Life Science
Buyer(s) Deerfield Management
Deal Type Going Private
Advisor(s) Gunderson Dettmer (Legal)

Target

Singular Genomics

San Diego, California, United States
Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. Its G4 Sequencing Platform is a versatile benchtop genomic sequencer designed to produce fast and accurate results. The company currently developing the G4X Spatial Sequencer, which will leverage its proprietary sequencing technology, applying it as an in situ readout for transcriptomics, proteomics, and fluorescent H&E in tissue, with spatial context and on the same platform as the G4.. Singular Genomics was formed in 2016 and is based in San Diego, California.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Deerfield Management

Investor Investor Investor Investor Investor

Category Venture Capital Firm
Founded 1994
PE ASSETS 15.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

Deerfield Management is a hedge fund sponsor focused on public and private company investments in the healthcare sector. Deerfield was established in 1994 and is headquartered in New York, New York.

DEAL STATS #
Overall 6 of 6
Sector: Life Science M&A 3 of 3
Type: Going Private M&A Deals 2 of 2
State: California M&A 3 of 3
Country: United States M&A 6 of 6
Year: 2024 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-03-18 Adaptive Phage Therapeutics

Gaithersburg, Maryland, United States

Adaptive Phage Therapeutics is a U.S.-based privately-held, clinical-stage biotechnology company developing phage-based therapies to combat bacterial infections. Adaptive Phage Therapeutics is based in Gaithersburg, Maryland.

Sell -
Mergr

Solution for

Product

Company

Legal